NEW YORK (GenomeWeb) – Locus Biosciences said today that is has acquired EpiBiome's high-throughput bacteriophage discovery platform.

Locus is developing CRISPR-Cas3-engineered precision antibacterial products, and aims to pair EpiBiome's phage isolation and characterization system with its own CRISPR-based synthetic biology platform to develop products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.